Clinical trials: Cancer of Thorax
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Carcinoma, Non-Small-Cell Lung
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To collect information of safety in patients with unresectable advanced or recurrent non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other platinum-based anti-cancer agents under actual use in…
- Trial name
- NCT05826366
- Where
- 28 sites in Japan
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Neoplasms (Cancer / Tumors), Colorectal Neoplasms
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment
Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typically using immunohistochemistry or sequencing.
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms
- Trial name
- FATHOM (NCT07814872)
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Covid-19, Lung Cancer
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection.
- Trial name
- GRAVID (NCT04344002)
- Where
- 75 sites in Spain
- Volunteers
- 886 people
- Sponsor
- Spanish Lung Cancer Group
Breast Cancer, Cancer
Vinorelbine and XR9576 to Treat Cancer
Tumor resistance to anti-cancer drugs is a major problem in cancer treatment. Studies have found that a protein (P-glycoprotein) on some cancer cells pumps chemotherapy drugs out of the cells, reducing treatment effectiveness.
- Conditions
- Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00001944
- Testing
- Vinorelbine, XR9576
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lung Adenocarcinoma, Surgery
DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma
This study is designed to assess DNA 5-methylcytosine (5mC) methylation modifications in lung adenocarcinoma (LUAD) samples and develop a prognosis-predictive model for LUAD based on cancer tissue DNA 5mC levels.
- Conditions
- Lung Adenocarcinoma, Surgery, Prognostic Cancer Model
- Trial name
- NCT06477211
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Nanjing University
Lung Cancer
Surveillance For New Lung Primaries
The primary goal of this study is to determine the prevalence of tracheobronchial carcinomas in patients with a history of squamous cell cancer of the aerodigestive tract who have been treated with a curative intent and remain…
- Trial name
- NCT00205439
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Wisconsin, Madison
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.
- Trial name
- NCT00590902
- Testing
- OSI-774: erlotinib, TarcevaTM
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Retifanlimab and Ruxolitinib In Solid Malignancies
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma.
- Trial name
- PRISM (NCT07219576)
- Testing
- Ruxolitinib, Retifanlimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question[s] it aims to answer is: provide a basis for accurate staging and the relationship between OS and…
- Trial name
- NCT05604664
- Where
- China
- Volunteers
- 1,727 people
- Sponsor
- Yongtao Han
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET)
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One…
- Conditions
- Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
- Trial name
- NCT01222767
- Testing
- Zalypsis
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- PharmaMar
Lung Cancer
Microwave Ablation in Pulmonary Malignancies
Lung cancer remains to be an important global issue as it is the leading cause of cancer_ related mortality for both men and women worldwide .Since more than two thirds of cases are diagnosed at an advanced stage,the survival…
- Trial name
- NCT04081181
- Testing
- Microwave ablation
- Volunteers
- 19 people
- Sponsor
- Assiut University
SMARCA4-Deficient Tumor, NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer
This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).
- Trial name
- NCT07121387
- Where
- China
- Volunteers
- 221 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer, Image, Body
Influence of PET/CT Radiomic Features on the Outcome of Lung Cancer Patients
Radiomics is an attractive field in objectively quantifying image features, and may overcome the subjectivity of visually interpreting computed tomography (CT), or positron emission tomography (PET).
- Trial name
- NCT03648151
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Shanxi Medical University
Lung Cancer (Diagnosis)
A Multicenter, Prospective Study on the Diagnostic Efficacy of Femtosecond Laser Label-Free Imaging Combined With Artificial Intelligence-Assisted Diagnosis for Rapid Diagnosis of Lung Cancer Surgical Specimens
To investigate the diagnostic efficacy of Femtosecond Laser Label-Free Imaging combined with artificial intelligence-assisted diagnosis for rapid diagnosis of lung cancer.
- Trial name
- NCT07794449
- Testing
- Femtosecond Laser Label-Free Imaging Combined with Artificial Intelligence
- Volunteers
- 335 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Cancer Stage IV, Lung Cancer, Non-small Cell
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Immune-checkpoint inhibitors have recently become available as a new therapy for a variety of cancers. This drugs function by boosting the anti-cancer immune response, but unfortunately, may cause off-target, non-specific immune…
- Conditions
- Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
- Trial name
- NCT04595734
- Testing
- No intervention due to observational methods of study
- Where
- 3 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Pneumothorax Spontaneous Primary, Pneumothorax Spontaneous Secondary
Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis
Pleural effusion is characterized by the accumulation of fluid in the pleural space, which typically contains about 10-20 mL of pleural fluid that is crucial for the movement of the lungs against the chest wall.
- Conditions
- Pneumothorax Spontaneous Primary, Pneumothorax Spontaneous Secondary, Pleural Effusion, Malignant, Pleurodesis
- Trial name
- NCT07167992
- Testing
- Pleurodesis
- Where
- Pakistan
- Volunteers
- 160 people
- Sponsor
- University of Health Sciences Lahore